Cotiviti Taps Tech Veteran Ric Sinclair as CEO for Next Growth Phase

SALT LAKE CITY, UT – March 09, 2026

Cotiviti, a heavyweight in the healthcare technology sector, has announced a strategic leadership transition aimed at accelerating its next phase of growth and innovation. Effective March 16, 2026, seasoned technology executive Ric Sinclair will take the helm as Chief Executive Officer and join the Board of Directors. He succeeds Dr. Emad Rizk, who after a transformative decade as CEO, will transition to a new role as Senior Advisor to the Board and executive team.

The move signals a deliberate pivot by Cotiviti and its private equity backers, Veritas Capital and KKR, to intensify the company's focus on platform-led innovation. Sinclair's appointment is seen by industry analysts as a clear indicator of the company's intent to double down on its technology stack and data analytics capabilities to address persistent inefficiencies in the U.S. healthcare system.

A New Era of Platform-Led Innovation

Ric Sinclair joins Cotiviti from Waystar, a healthcare payment technology provider, where he served as Chief Business Officer. At Waystar, and its predecessor ZirMed, Sinclair was a pivotal figure in building and scaling a high-growth, enterprise-grade technology platform that streamlined the notoriously complex healthcare revenue cycle. His deep experience spans enterprise strategy, product management, commercialization, and mergers and acquisitions—a skill set that aligns precisely with Cotiviti's strategic ambitions.

During his tenure at Waystar, Sinclair was instrumental in expanding the company into new markets and launching numerous product lines that earned accolades for innovation. His track record is built on translating complex market needs into scalable technology solutions, a background that Cotiviti's board is betting on to unlock new value from its vast data assets.

“I’m excited to join Cotiviti at a defining moment in its journey,” Sinclair stated in the official announcement. “With our exceptional team and solid foundation, we are uniquely positioned to shape the next era of healthcare innovation. My priority is to accelerate this transformation — unlocking efficiency, reducing complexity, and delivering measurable improvements across both medical and administrative challenges for all stakeholders in healthcare.”

Sinclair’s appointment reflects a broader trend in the health-tech industry, where deep technological and product expertise is increasingly viewed as a prerequisite for top leadership roles. The challenge ahead for Sinclair will be to unify Cotiviti's extensive but disparate data and technology assets—bolstered by acquisitions like Edifecs—into a more integrated and frictionless ecosystem.

The Legacy of a Transformative Decade

The leadership transition marks the end of a significant chapter for Cotiviti under Dr. Emad Rizk. Over the past ten years, Dr. Rizk guided the company through a period of substantial evolution, cementing its position as an industry leader in payment accuracy, risk adjustment, and quality improvement solutions. His tenure was marked by several transformational acquisitions and strategic partnerships that dramatically expanded the company's market presence and capabilities.

Under his leadership, Cotiviti grew to serve a vast portion of the U.S. healthcare system, with its solutions impacting over 300 million members and patients. He successfully navigated the company through its 2018 acquisition by Verscend Technologies, a Veritas Capital portfolio company, and the subsequent landmark deal in February 2024 where KKR acquired a majority stake, valuing Cotiviti at an estimated $10-11 billion.

“Leading Cotiviti has been a privilege,” said Dr. Rizk. “I am thankful for the dedication of the senior leadership team and the commitment of our owner-employees. Together, we built a resilient foundation and cultivated a culture built on respect and excellence... I am confident the organization is well positioned to continue delivering meaningful impact across the healthcare ecosystem.”

Both Veritas and KKR lauded Dr. Rizk's contributions. Ramzi Musallam, CEO of Veritas, expressed his “deepest gratitude” for Dr. Rizk's “insightful leadership and steadfast commitment.” Max Lin, a Partner at KKR, credited his “exemplary leadership and unwavering dedication” for building Cotiviti’s robust foundation.

Strategic Imperatives from Private Equity Backers

The leadership change is a strategic move orchestrated by Cotiviti's powerful private equity owners, who are focused on maximizing the value of their significant investment. For KKR, which took a majority stake in 2024, and long-term investor Veritas Capital, Sinclair represents the ideal leader to drive the next stage of value creation.

Both firms have a well-defined playbook for their technology and healthcare investments: drive growth through organic product development, pursue strategic acquisitions, and optimize operations for efficiency and scale. Sinclair's background in scaling a high-growth platform at Waystar makes him a natural fit for executing this strategy. His appointment strongly suggests that Cotiviti's owners are preparing the company for an aggressive push to consolidate its market position and expand its technological edge over competitors like Optum and IQVIA.

The high valuation placed on Cotiviti during the KKR transaction underscores the immense expectations for the company's performance. The new CEO will be tasked with delivering on the promise of Cotiviti's integrated platform, leveraging AI and advanced analytics to generate substantial returns by tackling the estimated $12 billion in inefficiency and waste the company addresses annually.

Redefining Healthcare Efficiency

Ultimately, the success of this transition will be measured by its impact on the healthcare industry itself. Cotiviti operates at the critical intersection of payers and providers, a space fraught with administrative friction and financial waste. The company’s core mission is to bring transparency and efficiency to this ecosystem, helping clients reduce costs while improving care quality.

Under Sinclair, Cotiviti is expected to accelerate its use of responsible AI and machine learning, which it already applies to payment integrity and clinical chart validation. The goal is to move beyond simply identifying errors to proactively preventing them, reducing the administrative burden on both sides of the healthcare equation. Sinclair's vision of a “frictionless ecosystem” speaks directly to the needs of clients struggling with data silos and operational complexity.

For the more than 200 healthcare payers and health systems that rely on Cotiviti, the new leadership promises a renewed focus on delivering measurable outcomes. By enhancing the performance of its core solutions in payment accuracy, risk adjustment, and quality, Cotiviti aims to solidify its role as an indispensable partner in the industry's ongoing shift toward value-based care and greater financial accountability.